Melanoma Clinical Trials in Maryland

Showing 261-280 of 318 trials

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

NCT01014351

Based on data demonstrating synergy between paclitaxel and mammalian target of rapamycin (mTOR) inhibition, the investigators propose that the addition of everolimus to paclitaxel with carboplatin should lead to improvements in efficacy as measured by progression-free survival and response rate.

Metastatic Melanoma

SCRI Development Innovations, LLC70 participantsStarted Feb 2010

Fort Myers, Florida, United States • Gainesville, Georgia, United States • Evansville, Indiana, United States +9 more locations

COMPLETEDPhase 217 miles

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

NCT00032045

RATIONALE: Vaccines made from peptides may make the body build an immune response to kill tumor cells. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining vaccine therapy with a monoclonal antibody may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with monoclonal antibody therapy in treating patients who have stage IV melanoma.

Intraocular MelanomaMelanoma (Skin)

National Cancer Institute (NCI)Started Jan 2002

Bethesda, Maryland, United States

Study of Everolimus With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Melanoma Trials in Other Cities

Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Vaccine Therapy With High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in Maryland